Literature DB >> 15188671

Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.

S Smeland1, T Wiebe, T Böhling, O Brosjö, K Jonsson, T A Alvegård.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15188671     DOI： 10.1080/00016470410001708380

Source DB:  PubMed          Journal:  Acta Orthop Scand Suppl        ISSN： 0300-8827


× No keyword cloud information.
  7 in total

1.  18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Authors:  Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong
Journal:  Skeletal Radiol       Date:  2011-02-06       Impact factor: 2.199

Review 2.  Current strategies of chemotherapy in osteosarcoma.

Authors:  Dorothe Carrle; Stefan S Bielack
Journal:  Int Orthop       Date:  2006-08-03       Impact factor: 3.075

Review 3.  Surgical intervention for pulmonary metastases.

Authors:  Joachim Pfannschmidt; Gerlinde Egerer; Marc Bischof; Michael Thomas; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2012-10-05       Impact factor: 5.594

4.  EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

Authors:  Fateme Haghiralsadat; Ghasem Amoabediny; Samira Naderinezhad; Kamran Nazmi; Jantine Posthuma De Boer; Behrouz Zandieh-Doulabi; Tymour Forouzanfar; Marco N Helder
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

5.  Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.

Authors:  Yool Cho; Gu-Hee Jung; So-Hak Chung; Ji-Yeon Kim; Young Choi; Jae-Do Kim
Journal:  Clin Orthop Surg       Date:  2011-02-15

6.  Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study.

Authors:  Hairong Xu; Zhen Huang; Yuan Li; Qing Zhang; Lin Hao; Xiaohui Niu
Journal:  Cancer Biol Med       Date:  2019-02       Impact factor: 4.248

7.  Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.

Authors:  Jantine Posthumadeboer; Pim W van Egmond; Marco N Helder; Renée X de Menezes; Anne-Marie Cleton-Jansen; Jeroen A M Beliën; Henk M W Verheul; Barend J van Royen; Gert-Jan J L Kaspers; Victor W van Beusechem
Journal:  Oncotarget       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.